By Catherine Eckford2024-03-26T15:43:26
Phase III data shows that mRNA-1283 has a similar safety profile to Moderna's approved COVID-19 vaccines, the company states.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-03T12:02:00Z
2026-06-01T10:49:00Z
2026-06-01T08:21:00Z
Sponsored by Gilson
2026-05-27T11:39:00Z
2026-05-25T10:00:00Z
By Crystal Allard and Pratyusha Pallavi
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2025-10-22T14:00:00
Sponsored by Bruker
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
Site powered by Webvision Cloud